Amy Beres

1.1k total citations
9 papers, 870 citations indexed

About

Amy Beres is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, Amy Beres has authored 9 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Hematology and 2 papers in Oncology. Recurrent topics in Amy Beres's work include Hematopoietic Stem Cell Transplantation (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (5 papers). Amy Beres is often cited by papers focused on Hematopoietic Stem Cell Transplantation (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (5 papers). Amy Beres collaborates with scholars based in United States. Amy Beres's co-authors include William R. Drobyski, Richard Komorowski, Masahiko Mihara, Rupali Das, Xiaohong Chen, Martin J. Hessner, Amelia E. Barber, Clive N. Svendsen, Allison D. Ebert and Dario A.A. Vignali and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Immunity.

In The Last Decade

Amy Beres

8 papers receiving 861 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Beres United States	6	598	261	220	126	64	9	870
Robert Bayer United States	17	121 0.2×	215 0.8×	262 1.2×	131 1.0×	68 1.1×	23	754
Guy Mouchiroud France	16	300 0.5×	138 0.5×	133 0.6×	292 2.3×	22 0.3×	42	700
Gillian A. Kingsbury United States	12	334 0.6×	99 0.4×	194 0.9×	163 1.3×	24 0.4×	19	708
Serena De Vita United States	13	114 0.2×	157 0.6×	118 0.5×	283 2.2×	59 0.9×	29	621
Heather A. O’Leary United States	14	180 0.3×	360 1.4×	236 1.1×	314 2.5×	72 1.1×	26	869
Masato Okada Japan	14	457 0.8×	91 0.3×	71 0.3×	174 1.4×	48 0.8×	47	880
Vadim Y. Taraban United Kingdom	15	746 1.2×	29 0.1×	326 1.5×	167 1.3×	60 0.9×	24	1.0k
Amélie Benoit de Coignac France	9	339 0.6×	40 0.2×	216 1.0×	209 1.7×	52 0.8×	10	671
Vanessa Beynon United States	16	393 0.7×	68 0.3×	105 0.5×	283 2.2×	12 0.2×	19	901
Can Küçük Türkiye	14	470 0.8×	103 0.4×	488 2.2×	398 3.2×	96 1.5×	36	1.3k

Countries citing papers authored by Amy Beres

Since Specialization

Citations

This map shows the geographic impact of Amy Beres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Beres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Beres more than expected).

Fields of papers citing papers by Amy Beres

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Beres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Beres. The network helps show where Amy Beres may publish in the future.

Co-authorship network of co-authors of Amy Beres

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Beres. A scholar is included among the top collaborators of Amy Beres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Beres. Amy Beres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Weese, James L., et al.. (2020). Use of treatment pathways reduce cost and increase entry into clinical trials in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). e21000–e21000.

2.

Turnis, Meghan E., Deepali V. Sawant, Andrea L. Szymczak-Workman, et al.. (2016). Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 44(2). 316–329. 243 indexed citations

3.

Zhang, Qianxia, Amy Beres, & Dario A.A. Vignali. (2014). Regulatory T cells use LAG-3 as the “brake” in autoimmune diabetes but the “accelerator” in tumor environment (IRC4P.487). The Journal of Immunology. 192(Supplement_1). 60.14–60.14. 1 indexed citations

4.

Beres, Amy & William R. Drobyski. (2013). The Role of Regulatory T Cells in the Biology of Graft Versus Host Disease. Frontiers in Immunology. 4. 163–163. 96 indexed citations

5.

Beres, Amy, et al.. (2012). CD8+ Foxp3+ Regulatory T Cells Are Induced during Graft-versus-Host Disease and Mitigate Disease Severity. The Journal of Immunology. 189(1). 464–474. 97 indexed citations

6.

Beres, Amy, Richard Komorowski, Masahiko Mihara, & William R. Drobyski. (2011). Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host Disease. Clinical Cancer Research. 17(12). 3969–3983. 73 indexed citations

7.

Beres, Amy, et al.. (2011). Induction of a Novel Population of CD8+ Foxp3+ Regulatory T Cells During Graft Versus Host Disease. Blood. 118(21). 821–821. 1 indexed citations

8.

Chen, Xiaohong, Rupali Das, Richard Komorowski, et al.. (2009). Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 114(4). 891–900. 230 indexed citations

9.

Ebert, Allison D., Amy Beres, Amelia E. Barber, & Clive N. Svendsen. (2007). Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease. Experimental Neurology. 209(1). 213–223. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact